NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Development of a Silica Microparticle Taggant System to Measure ART Adherence

WithdrawnNA

Sponsor: Brigham and Women's Hospital

Conditions: Hiv, Medication Adherence, Compliance, Medication

Interventions: TruTag System, Biktarvy Pill

Developing technologies to help measure and provide tools to support medication-taking behaviors (medication adherence) is an important step to ending the human immunodeficiency virus (HIV) epidemic. TruTag Technologies has pioneered the use of a microparticle system that can be incorporated into the coating of medications may help users both identify the medication they are taking and record adherence events. By using a standard smartphone camera, shining light on TruTag-coated medications automatically identifies them to an onboard smartphone app which then indirectly records the adherence event. This study evaluates the real-world usability and feasibility of operating this system among people living with HIV (PLWH).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Age 18 or older
2. Living with HIV
3. Currently prescribed and taking Biktarvy as ART for at least 3 months
4. Undetectable viral load in prior 6 months
5. Owns iPhone model 11 or higher (non-SE only)

Exclusion Criteria:

1. Not English-speaking
2. Unwilling to interact with the TruTag app